In vivo evolution of CTX-M-215, a novel narrow-spectrum β-lactamase in an Escherichia coli clinical isolate conferring resistance to mecillinam.,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

In vivo evolution of CTX-M-215, a novel narrow-spectrum β-lactamase in an Escherichia coli clinical isolate conferring resistance to mecillinam.
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2020-10-20 , DOI: 10.1128/aac.00562-20
Mengyun Yin _{1,

2} , Guoping Hu ₃ , Zhen Shen ₄ , Chengli Fang _{5,

6} , Xuefei Zhang _{1,

2} , Dan Li _{1,

2} , Yohei Doi ₇ , Yu Zhang _{5,

6} , Minggui Wang _{2,

8} , Qinglan Guo _{2,

8}

Affiliation

Here, we report a novel narrow-spectrum β-lactamase CTX-M-215 identified in an Escherichia coli clinical isolate in China and conferring high-level resistance to mecillinam but not to cefotaxime. CTX-M-215 differed from CTX-M-125, a CTX-M extended-spectrum β-lactamase (ESBL), by an N132D substitution, which decreased hydrolytic activities toward penicillins and cephalosporins except for mecillinam. High similarity was observed between CTX-M-215- and CTX-M-125-bearing plasmids, carried by different isolates in the same patient, indicating in vivo evolution of CTX-M-215 from CTX-M-125.

更新日期：2020-10-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11